4708例急性髓系白血病患者CEBPA突变分析:bZIP与TAD突变对预后的差异影响
该回顾性研究分析了4708例成人AML患者,检出240例(5.1%)CEBPA突变,其中双等位突变131例、单等位突变109例。单等位bZIP突变与双等位突变临床特征相似且预后较好,而单等位TAD突变预后差;框内bZIP突变(CEBPAbZIP-inf)是预后良好的关键亚型。
要点
- CEBPA双等位突变和单等位bZIP突变患者中位OS分别为103和63个月,优于单等位TAD突变的13个月。
- 框内bZIP突变(CEBPAbZIP-inf)才与良好预后相关,非框内bZIP突变不具此优势。
- 单等位TAD突变患者年龄较大、白细胞计数较低,且NPM1共突变率较高。
核心结论
- CEBPA单等位bZIP突变(尤其框内突变)与双等位突变预后相似且良好,而单等位TAD突变预后差。
研究设计与样本
- 回顾性分析4708例纳入Study Alliance Leukemia试验的成人急性髓系白血病患者。
主要发现
- 240例(5.1%)检出CEBPA突变:131例双等位,109例单等位(60例TAD,49例bZIP)。
- 双等位和单等位bZIP突变者中位年龄46和50岁,中位WBC 23.7×10^9/L和35.7×10^9/L,均低于单等位TAD突变者的63岁和13.1×10^9/L(P<.001)。
- GATA2突变率在双等位和单等位bZIP突变中为35.1%和36.7%,高于单等位TAD突变的6.7%(P<.001)。
- NPM1突变率在双等位和单等位bZIP突变中为3.1%和8.2%,低于单等位TAD突变的38.3%(P<.001)。
- 双等位和单等位bZIP突变中位OS为103和63个月,中位EFS为20.7和17.1个月,均优于单等位TAD突变的13个月和5.7个月。
关键数值与推荐
- CEBPA突变检出率5.1%(240/4708)。
- 双等位突变中位OS 103个月、EFS 20.7个月;单等位bZIP突变中位OS 63个月、EFS 17.1个月;单等位TAD突变中位OS 13个月、EFS 5.7个月。
- 框内bZIP突变(CEBPAbZIP-inf)患者完全缓解率更优,中位OS和EFS最长。
临床怎么用
- 对AML患者进行CEBPA突变分型时,应区分双等位、单等位bZIP(尤其框内)和单等位TAD突变以评估预后。
- 框内bZIP突变可考虑作为预后良好标志,而单等位TAD突变预后较差需更积极治疗。
局限性
- 回顾性分析,结果需前瞻性验证。
- 样本来自临床试验人群,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biallelic mutations of the CEBPA gene (CEBPAbi) define a distinct entity associated with favorable prognosis; however, the role of monoallelic mutations (CEBPAsm) is poorly understood. We retrospectively analyzed 4708 adults with acute myeloid leukemia (AML) who had been recruited into the Study Alliance Leukemia trials, to investigate the prognostic impact of CEBPAsm. CEBPA mutations were identified in 240 patients (5.1%): 131 CEBPAbi and 109 CEBPAsm (60 affecting the N-terminal transactivation domains [CEBPAsmTAD] and 49 the C-terminal DNA-binding or basic leucine zipper region [CEBPAsmbZIP]). Interestingly, patients carrying CEBPAbi or CEBPAsmbZIP shared several clinical factors: they were significantly younger (median, 46 and 50 years, respectively) and had higher white blood cell (WBC) counts at diagnosis (median, 23.7 × 109/L and 35.7 × 109/L) than patients with CEBPAsmTAD (median age, 63 years, median WBC 13.1 × 109/L; P < .001). Co-mutations were similar in both groups: GATA2 mutations (35.1% CEBPAbi; 36.7% CEBPAsmbZIP vs 6.7% CEBPAsmTAD; P < .001) or NPM1 mutations (3.1% CEBPAbi; 8.2% CEBPAsmbZIP vs 38.3% CEBPAsmTAD; P < .001). CEBPAbi and CEBPAsmbZIP, but not CEBPAsmTAD were associated with significantly improved overall (OS; median 103 and 63 vs 13 months) and event-free survival (EFS; median, 20.7 and 17.1 months vs 5.7 months), in univariate and multivariable analyses. Additional analyses revealed that the clinical and molecular features as well as the favorable survival were confined to patients with in-frame mutations in bZIP (CEBPAbZIP-inf). When patients were classified according to CEBPAbZIP-inf and CEBPAother (including CEBPAsmTAD and non-CEBPAbZIP-inf), only patients bearing CEBPAbZIP-inf showed superior complete remission rates and the longest median OS and EFS, arguing for a previously undefined prognostic role of this type of mutation.
引用
- Taube F, Georgi JA, Kramer M, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022. PMID: 34320176. doi:10.1182/blood.2020009680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。